AU2020328590B2 - Tetracyclic compounds and their salts, compositions, and methods for their use - Google Patents

Tetracyclic compounds and their salts, compositions, and methods for their use

Info

Publication number
AU2020328590B2
AU2020328590B2 AU2020328590A AU2020328590A AU2020328590B2 AU 2020328590 B2 AU2020328590 B2 AU 2020328590B2 AU 2020328590 A AU2020328590 A AU 2020328590A AU 2020328590 A AU2020328590 A AU 2020328590A AU 2020328590 B2 AU2020328590 B2 AU 2020328590B2
Authority
AU
Australia
Prior art keywords
cancer
compound
mutation
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020328590A
Other languages
English (en)
Other versions
AU2020328590A1 (en
Inventor
John Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of AU2020328590A1 publication Critical patent/AU2020328590A1/en
Application granted granted Critical
Publication of AU2020328590B2 publication Critical patent/AU2020328590B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020328590A 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use Active AU2020328590B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US62/886,621 2019-08-14
US201962946774P 2019-12-11 2019-12-11
US62/946,774 2019-12-11
PCT/US2020/046329 WO2021030671A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Publications (2)

Publication Number Publication Date
AU2020328590A1 AU2020328590A1 (en) 2022-03-10
AU2020328590B2 true AU2020328590B2 (en) 2026-03-26

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020328590A Active AU2020328590B2 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Country Status (12)

Country Link
US (1) US20210046071A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013421A4 (cg-RX-API-DMAC7.html)
JP (1) JP7566010B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220130085A (cg-RX-API-DMAC7.html)
CN (1) CN114599368A (cg-RX-API-DMAC7.html)
AU (1) AU2020328590B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002784A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151112A1 (cg-RX-API-DMAC7.html)
IL (1) IL290626A (cg-RX-API-DMAC7.html)
PH (1) PH12022550360A1 (cg-RX-API-DMAC7.html)
TW (1) TW202114694A (cg-RX-API-DMAC7.html)
WO (1) WO2021030671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087235A1 (en) * 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101601332B1 (ko) * 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
EP3074391B1 (en) * 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
ES2959536T3 (es) 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
EP3752149A4 (en) * 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087235A1 (en) * 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nair AB, Jacob S. J Basic Clin Pharm. 2016 Mar;7(2):27-31. doi: 10.4103/0976-0105.177703. PMID: 27057123; PMCID: PMC4804402. https://pmc.ncbi.nlm.nih.gov/articles/PMC4804402/pdf/JBCP-7-27.pdf *
XU HONG, DI ANTONIO MARCO, MCKINNEY STEVEN, MATHEW VEENA, HO BRANDON, O’NEIL NIGEL J., SANTOS NANCY DOS, SILVESTER JENNIFER, WEI V: "CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours", NATURE COMMUNICATIONS, vol. 8, no. 1, XP093062967, DOI: 10.1038/ncomms14432 *

Also Published As

Publication number Publication date
JP2022544559A (ja) 2022-10-19
CN114599368A (zh) 2022-06-07
EP4013421A1 (en) 2022-06-22
WO2021030671A1 (en) 2021-02-18
IL290626A (en) 2022-04-01
BR112022002784A2 (pt) 2022-08-09
KR20220130085A (ko) 2022-09-26
CA3151112A1 (en) 2021-02-18
EP4013421A4 (en) 2023-08-23
US20210046071A1 (en) 2021-02-18
TW202114694A (zh) 2021-04-16
AU2020328590A1 (en) 2022-03-10
PH12022550360A1 (en) 2023-02-27
JP7566010B2 (ja) 2024-10-11

Similar Documents

Publication Publication Date Title
CN112955137B (zh) 组合疗法
US20220088029A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
US11524012B1 (en) Quinolone analogs and their salts, compositions, and method for their use
US20210046071A1 (en) Tetracyclic compounds and their salts, compositions, and methods for their use
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
CA2944255C (en) New derivatives of cephalosporin for treating cancer
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
CN115038447A (zh) 用于治疗癌症的组合疗法
CN112294813A (zh) 喹啉衍生物在治疗脊索瘤中的用途
CN103221050A (zh) 用于治疗增生性障碍的贝伐单抗与2,2-二甲基-N-((S)-6-氧代-6,7-二氢-5H-二苯并[b,d]氮杂*-7-基)-N`-(2,2,3,3,3-五氟-丙基)-丙二酰胺的组合
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
HK1233924B (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)